TAK-931 - A CDC7 Inhibitor in Solid Tumors | Dosage Collision Study Shows Treatment is Tolerable

TAK-931 - A CDC7 Inhibitor in Solid Tumors | Dosage Collision Study Shows Treatment is Tolerable

Annual-Meeting

1 year
184 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Ana Limon Carrera, Takeda Oncology, shares TAK-931 - A CDC7 Inhibitor in Solid Tumors | Dosage Collision Study Shows Treatment is Tolerable at Annual Meeting 2018
Up Next Autoplay